Files and links (1)
Published, Version of Record (VoR)CC BY-NC-SA V4.0, Open
Journal article
Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders
Expert opinion on pharmacotherapy, v 11(4), pp 637-648
01 Mar 2010
PMID: 20163274
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Importance of the field: Hyponatremia (serum sodium concentration < 136 mEq/liter) is a common and potentially life-threatening medical comorbidity seen in patients with psychotic disorders. Tolvaptan, a selective antagonist of the V2-receptor, is FDA-approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia. This represents a major development in the care of psychotic individuals with hyponatremia.
Areas covered in the review: This review provides an overview of the existing literature on prevalence rates and risk factors associated with hyponatremia in psychotic patients (1923 - present). Tolvaptan is discussed as a potential advance in the treatment of hyponatremia in patients with psychotic disorders, and preliminary data are reviewed.
What the reader will gain: The reader will gain an appreciation of the prevalence of hyponatremia among psychotic individuals, an understanding of the distinctions between acute and chronic hyponatremia in this population, and awareness that effective treatments are becoming available.
Take home message: A modest literature exists regarding prevalence rates and risk factors associated with hyponatremia in psychotic populations. Hyponatremia is common and serious enough to merit clinical concern. Perhaps, now that tolvaptan has been FDA-approved, progress will accelerate and new insights will develop that begin to bring relief from this medical comorbidity among psychotic patients.
Metrics
Details
- Title
- Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders
- Creators
- Richard C Josiassen - Drexel UniversityJessica Curtis - Montgomery County Community CollegeDawn M Filmyer - Translational Neuroscience, LLC, 180 Barren Hill Road, Conshohocken, PA 19428, USABrett Audino - Translational Neuroscience, LLC, 180 Barren Hill Road, Conshohocken, PA 19428, USANina Skuban - Worldwide Clinical TrialsRita A Shaughnessy - Drexel University
- Publication Details
- Expert opinion on pharmacotherapy, v 11(4), pp 637-648
- Publisher
- Informa UK Ltd
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Psychiatry
- Web of Science ID
- WOS:000274885400013
- Scopus ID
- 2-s2.0-77249108996
- Other Identifier
- 991019167726304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy